Drug Trial Radar · NCT05189210
GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)
Last checked: Nov 19, 2026Latest source record: Sep 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
199
Actual
Start
Oct 5, 2022
Primary completion
Apr 3, 2025
Study completion Apr 16, 2025
Sponsor
- Lead sponsor
- GemVax & KaelIndustry
- Sponsor type
- Industry
- First posted
- Jan 12, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The current study is being conducted by the Sponsor to evaluate the efficacy and safety of GV1001 (0.56 mg and 1.12 mg) administered subcutaneously as a treatment for mild to moderate Alzheimer's disease (AD). Studies using in vivo and in vitro AD models have shown that GV1001 inhibits neurotoxicity, apoptosis, and the production of reactive oxygen species induced by amyloid beta (Aβ) in neural stem cells by mimicking the extra-telomeric functions of human telomerase reverse transcriptase (hTERT). In nonclinical studies, using both mild (early stage) and severe (late stage) AD mouse models, GV1001 was shown to improve cognitive function and memory, as well as significantly reduce the amount of Aβ and tau proteins. The multifunctional effect of GV1001 makes it a promising therapeutic option for the treatment for AD. In a completed Phase 2 study conducted in Korea, GV1001 showed significant improvement in change from baseline of Severe Impairment Battery score at Week 24 and demonstrated a clinically acceptable safety profile in patients with moderate to severe AD.
Conditions
- Mild to Moderate Alzheimer's Disease
Interventions
GV1001 PlaceboDrug
0.9% normal saline
GV1001 0.56mgDrug
Lyophilized peptide from hTERT
GV1001 1.12mgDrug
Lyophilized peptide from hTERT
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in ADAS-Cog11 score at Week 52Time frame: Baseline, Week 12, Week 26, Week 38, and Week 52
Locations
35 sites in 8 countries. Site status is shown where the registry gives one.
First Choice Neurology - Aventura Neurologic Associates
Adventura, Florida
Finlay Medical Research Corporation - Greenacres
Greenacres City, Florida
Outpatient Psy Care
Miami, Florida
Finlay Medical Research Corporation - Miami Dade
Miami, Florida
Aqualane Clinical Research
Naples, Florida
Palm Beach Neurological Center
Palm Beach Gardens, Florida
Neurostudies - Port Charlotte
Port Charlotte, Florida
Palm Beach Neurology and Premiere Research Institute
West Palm Beach, Florida
Accel Research Sites (ARS) - NeuroStudies
Decatur, Georgia
Global Medical Institutes - Princeton Medical Institute
Princeton, New Jersey
Flourish Research - Alzheimer's Memory Center/AMC Research, LLC
Charlotte, North Carolina
Neurology Clinic - Cordova
Cordova, Tennessee
Terveystalo Oulu
Oulu, Finland
Hôpital La Grave
Toulouse, Midi-Pyrenees, France
Hôpital Pierre Wertheimer
Bron, Rhône, France
Casa di Cura iGEA SpA c/o Casa di Cura Privata del Policlinico
Milan, Italy
Brain Research Centre - Den Bosch
Amsterdam, Netherlands
Brain Research Center - Amsterdam
Amsterdam, North Holland, Netherlands
Brain Research Center - Zwolle
Zwolle, Overijssel, Netherlands
Centrum Medyczne Neuromed - Ośrodek Badań Klinicznych
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Wroctawskie Centrum Alzheimerowskie (WCA)
Wroclaw, Lower Silesian Voivodeship, Poland
Galen Clinic
Lublin, Lublin Voivodeship, Poland
Centrum Medyczne Neuroprotect
Warsaw, Masovian Voivodeship, Poland
Niepubliczny Zakład Opieki Zdrowotnej NOVO-MED
Katowice, Silesian Voivodeship, Poland
Clinhouse Centrum Medyczne
Zabrze, Silesian Voivodeship, Poland
Unidade Local de Saúde de Braga, E. P. E (Hospital de Braga)
Braga, Portugal
Unidade Local de Saúde de Santa Maria, E. P. E. - Hospital de Santa Maria
Lisbon, Lisbon District, Portugal
Hospital Pedro Hispano
Senhora da Hora, Porto District, Portugal
Hospital Universitari Vall d'Hebrón
Barcelona, Spain
Hospital Clinic de Barcelona
Barcelona, Spain
Fundacio ACE
Barcelona, Spain
Hospital Victoria Eugenia
Seville, Spain
Hospital Universitario Virgen del Rocío
Seville, Spain
Hospital Universitari i Politècnic La Fe
Valencia, Spain
Hospital Universitario Quirónsalud Madrid
Pozuelo de Alarcón, Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.